drugset / Trial / NCT01237444

Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.

NCT01237444

Phase 3 Completed 417 enrolled Pedro Cahn Abbott · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is designed to compare the safety, tolerability, antiviral activity and immunological effect of lopinavir/ritonavir plus lamivudine (3TC) versus standard therapy with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus lopinavir/ritonavir in the treatment of naïve HIV-1 infected subjects.

Timeline

Start
2010-12
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lamivudine Other / unclassified 150 mg Oral
Comparator Lopinavir Other / unclassified 400 mg Oral
Comparator Ritonavir Other / unclassified 100 mg Oral
Comparator emtricitabine Other / unclassified 200 mg Oral